#USA #San Francisco #Liquid Biopsy #LuminoDx #HepatoTrack

LuminoDx to Present HepatoTrack at the World Transplant Congress

LuminoDx, a leader in diagnostic innovation, is excited to announce that it will be showcasing its latest advancements at the World Transplant Congress in San Francisco. The spotlight will be on HepatoTrack, the company’s flagship liquid biopsy test designed to predict liver transplant rejection.

The Importance of HepatoTrack

HepatoTrack stands out in the realm of liver transplant management due to its CLIA certification and ability to correlate more effectively with acute cellular rejection (ACR) compared to standard liver tests like AST and ALT. This less invasive method is not only quicker but also offers a more cost-efficient alternative to traditional tissue biopsies. The test is pivotal for clinicians, especially in post-transplant care, allowing them to monitor liver health in real-time as they adjust immunosuppressive therapy.

Yipeng Wang, the co-founder and CEO of LuminoDx, commented on the significance of the HepatoTrack test: "Our technology empowers physicians to quickly assess the liver's health status, which is crucial when managing and reducing immunosuppressive therapies after a transplant."

A Strong Expertise Behind the Product

The scientific expertise at LuminoDx is notable, with co-founders Gordon Vansant and Yipeng Wang possessing extensive experience in assay development and liquid biopsy techniques. Their work includes advancing molecular and proteomic assays while supporting therapeutic drug development through rigorous clinical studies. Gordon Vansant, who also serves as the Chief Business Officer, emphasizes the importance of the HepatoTrack test in assisting transplant physicians: "With HepatoTrack, we equip medical professionals with critical data to ensure safe management of immunosuppression, which is crucial for patient outcomes."

Innovation in Action

Founded in San Diego, LuminoDx specializes in liquid biopsy and molecular testing, boasting over 80 years of collective experience in diagnostic development. The company’s commitment is to provide innovative solutions that enhance clinical applications and research initiatives. Their liquid biopsy platform for post-liver transplant care allows precise monitoring of allograft health, helping to fine-tune immunosuppression dosages and mitigate the risks of complications.

In addition to HepatoTrack, LuminoDx offers various services, including advanced proteomics analysis through Olink, ELISA testing, spatial biology systems, and the development of laboratory tests tailored to specific needs. This holistic approach signifies LuminoDx’s dedication to revolutionizing diagnostics and improving patient care in the transplantation field.

An Invitation to the Community

LuminoDx invites attendees of the World Transplant Congress to visit their exhibition space to learn more about HepatoTrack and its impact on liver transplant management. The company is eager to engage with healthcare professionals and discuss the future of diagnostics in transplantation.

For more information about LuminoDx and their pioneering solutions, visit www.luminodx.com.

With HepatoTrack, LuminoDx aims to transform the landscape of post-transplant monitoring, ultimately leading to better patient outcomes and a more effective approach to immunosuppression management.